Yahoo Finance

Jnana Therapeutics Reports Positive Topline Results from Phase 1a Clinical Study of JNT-517, a Potential First-in-Class Oral Treatment for PKU

BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for ...
Yahoo Finance

Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU

BOSTON, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for ...
Business Wire

Jnana Therapeutics to Present Preclinical Data on its PKU Program at the 2023 Society for Inherited Metabolic Disorders Annual Meeting

BOSTON--(BUSINESS WIRE)--Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, will ...
JSTOR Daily

JNT: Journal of Narrative Theory,

JNT: Journal of Narrative Theory continues to follow the high standards set during its first four decades of publication; the newly focused JNT showcases theoretically sophisticated essays that ...